| Bioactivity | Acifran (AY 25712), an antihyperlipidemic agent, is an orally active agonist of GPR109A (HM74A) and GPR109B, the high and low affinity receptors for Niacin[1][2]. | |||||||||
| Name | Acifran | |||||||||
| CAS | 72420-38-3 | |||||||||
| Formula | C12H10O4 | |||||||||
| Molar Mass | 218.21 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. M N Cayen, et al. The metabolic disposition of acifran, a new antihyperlipidemic agent, in rats and dogs. Xenobiotica. 1986 Mar;16(3):251-63. [2]. Jae-Kyu Jung, et al. Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b. J Med Chem. 2007 Apr 5;50(7):1445-8. |